Striking costs of infertility point to importance of IVF access and affordability
By Beth Duff-Brown,
Stanford Institute for Economic Policy Research
| 07. 12. 2024
The debate over in vitro fertilization (IVF) has become a hot-button policy and political issue, despite the medical procedure to help people become pregnant having been mainstream in the United States for nearly half a century.
The Alabama Supreme Court recently ruled that embryos are children under the law — prompting at least three fertility clinics in that state to halt treatment — and more than a dozen other states are considering IVF restrictions. In June, the Southern Baptist Convention, the nation’s largest Protestant denomination, voted to oppose IVF treatments, while the U.S. Senate blocked legislation that would have made it a nationwide right for women to access fertility treatments.
These developments beg the question: How would making IVF unavailable affect the many couples who are building their dreams of a family on the use of this technology?
A new Stanford study provides novel, concrete evidence on how these involuntarily infertile couples are affected: infertility leads to poorer mental health among both partners and a hefty hike in the likelihood of divorce.
Petra Persson, an assistant professor of economics...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...